170 related articles for article (PubMed ID: 37314343)
1. Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
Tirlangi PK; Wanve BS; Dubbudu RR; Yadav BS; Kumar LS; Gupta A; Sree RA; Challa HPR; Reddy PN
Antimicrob Agents Chemother; 2023 Jun; 67(8):e0050023. PubMed ID: 37314343
[TBL] [Abstract][Full Text] [Related]
2. Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing
Egge SL; Lewis JS; Hakki M
Antimicrob Agents Chemother; 2023 Aug; 67(8):e0066323. PubMed ID: 37395652
[TBL] [Abstract][Full Text] [Related]
3. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
Dubey D; Roy M; Shah TH; Bano N; Kulshrestha V; Mitra S; Sangwan P; Dubey M; Imran A; Jain B; Velmurugan A; Bakthavatchalam YD; Veeraraghavan B
Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):55. PubMed ID: 37408075
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
[TBL] [Abstract][Full Text] [Related]
5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
6. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
[TBL] [Abstract][Full Text] [Related]
7. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
9.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
10.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
11. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A
J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659
[TBL] [Abstract][Full Text] [Related]
12. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
13. Transcending the challenge of evolving resistance mechanisms in
Hujer AM; Marshall SH; Mack AR; Hujer KM; Bakthavatchalam YD; Umarkar K; Palwe SR; Takalkar S; Joshi PR; Shrivastava R; Periasamy H; Bhagwat SS; Patel MV; Veeraraghavan B; Bonomo RA
mBio; 2023 Oct; 14(6):e0111823. PubMed ID: 37889005
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
15. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
16. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).
Soman R; Sirsat R; Sunavala A; Punatar N; Mehta J; Rodrigues C; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2024 Feb; ():. PubMed ID: 38416290
[TBL] [Abstract][Full Text] [Related]
18.
Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
[TBL] [Abstract][Full Text] [Related]
19. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
20.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
